Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 6OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3CNS 3Sarcoma 1Gynecologic 1

Conditions

Rhabdomyosarcoma 1

Interventions

Radiotherapy 35Doxorubicin 30Ifosfamide 29Cyclophosphamide 24Vincristine 23Filgrastim 23Etoposide 20Temozolomide 14Granulocyte Colony-Stimulating Factor 14Dactinomycin 11Cisplatin 11Trabectedin 10Methotrexate 10Gene Expression Profiling 10Radiation 9Imatinib Mesylate 9Surgical Procedures, Operative 8Polymerase Chain Reaction 8Irinotecan 8Specimen Handling 7Paclitaxel 7Chemotherapy, Adjuvant 7Mesna 6Immunohistochemistry 6Gemcitabine 6Carmustine 6Biopsy 6sargramostim 5pegfilgrastim 5etoposide phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Congresses as Topic × Sarcoma × Clear all
NCT00075582 2021-11-19

Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

Children's Oncology Group

Phase 3 Completed
390 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡